Oxford-AstraZeneca s Covishield is being manufactured by the Pune-based Serum Institute of India.
New Delhi:
Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday.
The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September.
The Hyderabad-based Bharat Biotech s indigenously developed Covaxin and Oxford-AstraZeneca s Covishield, being manufactured by the Pune-based Serum Institute of India, are currently being used in India s inoculation drive against coronavirus.
NEW DELHI: Fifty lakh doses of ‘Covishield vaccine earmarked by the Serum Institute for export to the United Kingdom have now been made available for the inoculation of 18-44 age group in 21 states/UTs in India, amid a surge in Covid-19 cases, official sources said.
The Centre s decision to allocate these doses to 21 states and Union territories (UTs) came after Prakash Kumar Singh, director, Government and Regulatory Affairs at Pune-based Serum Institute of India, recently wrote to the Union health ministry seeking permission for the same.
The Serum Institute had on March 23 sought permission from the ministry to supply 50 lakh doses of Covishield to the UK, citing an agreement with AstraZeneca in this regard, while assuring India that its own anti-coronavirus vaccination programme will not be disturbed due to this supply.
50 lakh Covishield doses meant for export to UK to be used in India for vaccinating 18-plus
SECTIONS
50 lakh Covishield doses meant for export to UK to be used in India for vaccinating 18-plusPTI
Last Updated: May 07, 2021, 08:27 PM IST
Share
Synopsis
The Centre s decision to allocate these doses to 21 states and Union territories (UTs) came after Prakash Kumar Singh, director, Government and Regulatory Affairs at Pune-based Serum Institute of India, recently wrote to the Union health ministry seeking permission for the same.
AFP
The Serum Institute had on March 23 sought permission from the ministry to supply 50 lakh doses of Covishield to the UK.
Highlights
A Petition has been filed in Bombay HC seeks Z+ security for Serum Institute of India CEO, his family
Petition informed the cough that Adar Poonawalla has been receiving threats from powerful persons
Mumbai: A writ petition has been filed in the Bombay High Court seeking Z plus security for Serum Institute of India CEO Adar Poonawalla and his family.
The petitioner, filed by advocate Datta Shrirang Mane, said that
Adar Poonawalla and his family should be given Z plus security, and his assets should be protected keeping the threats that were being made to Poonawallah as per media reports.